|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Moran C: Importance of molecular features
of non-small cell lung cancer for choice of treatment. Am J Pathol.
178:1940–1948. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salama JK and Vokes EE: New radiotherapy
and chemoradiotherapy approaches for non-small-cell lung cancer. J
Clin Oncol. 31:1029–1038. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pfister DG, Johnson DH, Azzoli CG, et al;
American Society of Clinical Oncology. American Society of Clinical
Oncology treatment of unresectable non-small-cell lung cancer
guideline: update 2003. J Clin Oncol. 22:330–353. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Furuse K, Fukuoka M, Kawahara M, et al:
Phase III study of concurrent versus sequential thoracic
radiotherapy in combination with mitomycin, vindesine, and
cisplatin in unresectable stage III non-small-cell lung cancer. J
Clin Oncol. 17:2692–2699. 1999.PubMed/NCBI
|
|
6
|
Okamoto I: Overview of chemoradiation
clinical trials for locally advanced non-small cell lung cancer in
Japan. Int J Clin Oncol. 13:112–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chang CC, Chi KH, Kao SJ, et al: Upfront
gefitinib/erlotinib treatment followed by concomitant radiotherapy
for advanced lung cancer: a mono-institutional experience. Lung
Cancer. 73:189–194. 2011. View Article : Google Scholar
|
|
8
|
Sato Y, Ebara T, Sunaga N, Takahashi T and
Nakano T: Interaction of radiation and gefitinib on a human lung
cancer cell line with mutant EGFR gene in vitro. Anticancer Res.
32:4877–4881. 2012.PubMed/NCBI
|
|
9
|
Nishie K, Kawaguchi T, Tamiya A, et al:
Epidermal growth factor receptor tyrosine kinase inhibitors beyond
progressive disease: a retrospective analysis for Japanese patients
with activating EGFR mutations. J Thorac Oncol. 7:1722–1727. 2012.
View Article : Google Scholar
|
|
10
|
Graham JD, Nahum AE and Brada M: A
comparison of techniques for stereotactic radiotherapy by linear
accelerator based on 3-dimensional dose distributions. Radiother
Oncol. 22:29–35. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Senan S: Surgery versus stereotactic
radiotherapy for patients with early-stage non-small cell lung
cancer: More data from observational studies and growing clinical
equipoise. Cancer. 119:2668–2270. 2013. View Article : Google Scholar
|
|
12
|
Rowe BP, Boffa DJ, Wilson LD, Kim AW,
Detterbeck FC and Decker RH: Stereotactic body radiotherapy for
central lung tumors. J Thorac Oncol. 7:1394–1399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Xia TY, Wang YJ, et al:
Prospective study of epidermal growth factor receptor tyrosine
kinase inhibitors concurrent with individualized radiotherapy for
patients with locally advanced or metastatic non-small-cell lung
cancer. Int J Radiat Oncol Biol Phys. 81:e59–e65. 2011. View Article : Google Scholar
|
|
14
|
Onal C, Abali H, Koc Z and Kara S:
Radiation recall pneumonitis caused by erlotinib after palliative
definitive radiotherapy. Onkologie. 35:191–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Zhu XX, Wu XH, et al: Gefitinib
combined with stereotactic radiosurgery in previously treated
patients with advanced non-small cell lung cancer. Am J Clin Oncol.
Dec 1–2012.(Epub ahead of print).
|
|
16
|
Yoshitake T, Nakamura K, Shioyama Y, et
al: Stereotactic body radiation therapy for stage I non-small cell
lung cancer patients with chronic respiratory insufficiency
requiring domiciliary oxygen therapy. Anticancer Res. 32:4041–4044.
2012.
|
|
17
|
Fukuoka M, Wu YL, Thongprasert S, et al:
Biomarker analyses and final overall survival results from a phase
III, randomized, open-label, first-line study of gefitinib versus
carboplatin/paclitaxel in clinically selected patients with
advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol.
29:2866–2874. 2011. View Article : Google Scholar
|
|
18
|
Takeda A, Kunieda E, Fujii H, et al:
Evaluation for local failure by 18F-FDG PET/CT in comparison with
CT findings after stereotactic body radiotherapy (SBRT) for
localized non-small-cell lung cancer. Lung Cancer. 79:248–253.
2013. View Article : Google Scholar : PubMed/NCBI
|
